000			01880 a2200529 4500
005			20250514053605.0
264		0	_c20030609
008			200306s 0 0 eng d
022			_a0953-7104
024	7		_a10.1080/0953710021000057839 _2doi
040			_aNLM _beng _cNLM
100	1		_aMazurov, A V
245	0	0	_aSafety, inhibition of platelet aggregation and pharmacokinetics of Fab'2 fragments of the anti-glycoprotein IIb-IIIa monoclonal antibody FRaMon in high-risk coronary angioplasty. _h[electronic resource]
260			_bPlatelets _cDec 2002
300			_a465-77 p. _bdigital
500			_aPublication Type: Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAbciximab
650	0	4	_aAngioplasty, Balloon, Coronary _xadverse effects
650	0	4	_aAnimals
650	0	4	_aAntibodies _xblood
650	0	4	_aAntibodies, Monoclonal _xadverse effects
650	0	4	_aEnzyme-Linked Immunosorbent Assay
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aImmunoglobulin Fab Fragments _xadverse effects
650	0	4	_aMale
650	0	4	_aMice
650	0	4	_aMiddle Aged
650	0	4	_aPlatelet Aggregation _xdrug effects
650	0	4	_aPlatelet Aggregation Inhibitors _xpharmacokinetics
650	0	4	_aPlatelet Count
650	0	4	_aPlatelet Glycoprotein GPIIb-IIIa Complex _ximmunology
650	0	4	_aReoperation
650	0	4	_aRisk Assessment
650	0	4	_aSafety
700	1		_aPevzner, D V
700	1		_aAntonova, O A
700	1		_aByzova, T V
700	1		_aKhaspekova, S G
700	1		_aSemenov, A V
700	1		_aVlasik, T N
700	1		_aSamko, A N
700	1		_aStaroverov, I I
700	1		_aRuda, M Ya
773	0		_tPlatelets _gvol. 13 _gno. 8 _gp. 465-77
856	4	0	_uhttps://doi.org/10.1080/0953710021000057839 _zAvailable from publisher's website
999			_c12292049 _d12292049